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In naive T cells, Lck exerts a negative control on the ERK/MAPK pathway. We show that c-mip (c-maf
inducing protein) interacts with the p85 subunit of PI3 kinase and inactivates Lck, which results in
Erk1/2 and p38 MAPK activation. This effect is not enough to activate AP1 given the inability of ERK
to migrate into the nucleus and to transactivate its target genes. We demonstrate that c-mip inter-
acts with Dip1 and upregulates DAPK, which blocks the nuclear translocation of ERK1/2. This dual
effect of c-mip is unique and might represent a potential mechanism to prevent the development
of an immune response.
Structured summary:
MINT-7383650: p85 (uniprotkb:P27986) physically interacts (MI:0915) with c-Mip (uniprotkb:Q8IY22) by
anti bait coimmunoprecipitation (MI:0006)
MINT-7383661: c-Mip (uniprotkb:Q8IY22) physically interacts (MI:0915) with p85 (uniprotkb:P27986) by
anti tag coimmunoprecipitation (MI:0007)
MINT-7383676: p85 (uniprotkb:P27986) physically interacts (MI:0915) with p110 (uniprotkb:P42336) by
anti bait coimmunoprecipitation (MI:0006)
MINT-7383689, MINT-7383711: Dip-1 (uniprotkb:Q80SY4) physically interacts (MI:0915) with c-Mip
(uniprotkb:Q8IY22) by anti tag coimmunoprecipitation (MI:0007)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cells respond to intra or extra cellular stimuli by engaging spe-
ciﬁc activation programs such as the signaling that leads to distinct
mitogen-activated protein kinase (MAPK) cascades. Among these,
the extra cellular signal regulated kinase (ERK1/2), c-jun N termi-
nal kinase and p38 MAPK pathways are the best characterized.
ERK1/2 are activated in response to growth factors via recruitment
of membrane receptor tyrosine kinases, G protein-coupled recep-
tors and integrins, whereas Jun N terminal kinase and p38 MAPK
are sensitive to stress stimuli [1]. In T cells, PKCh functions as a reg-
ulator of JNK activation [2]. The ERK1/2 proteins are recruited atchemical Societies. Published by E
ogram from INSERM, a grant
n pour l’Utilisation du Rein
Equipe 21, Créteil F-94010,most downstream in the signaling pathway where they play an
important role in the transmission of signals involved in a wide
range of cellular activities including proliferation, differentiation,
survival and apoptosis [3]. These functions are mediated through
sequential phosphorylation of diverse substrates such as phospho-
lipases, transcription factors and cytoskeleton proteins. The subcel-
lular localization of ERK1/2 determines their function: upon
activation, ERK1/2 are phosphorylated and translocate into the
nucleus while in unstimulated cells, they are sequestrated into
the cytoplasm in inactive form. A major target of ERK activation
is c-fos, a member of the AP1 transcription factor. It has been
shown that sustained ERK1/2 activation inﬂuences the nature of
AP1 complexes and upregulates the expression of cyclin D, allow-
ing cells to progress in cell-cycle and to induce the upregulation of
pro-proliferative genes [4]. In addition, recent studies show that
ERK1/2 are involved in the regulation of innate and adaptive
immunity [5]. The two isoforms of ERK, 42 and 44 kDa, are highly
homologous and possess the same substrate speciﬁcity. Althoughlsevier B.V. All rights reserved.
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form-speciﬁc invalidation in mice provides some differences. Thus,
loss of ERK2 leads to implantation defects and embryonic lethality,
whereas ERK1-deﬁcient mice exhibit a bias toward Th1 type im-
mune response and are susceptible to experimental autoimmune
encephalomyelitis [6].
In the course of studies molecular mechanisms underlying the
immunopathogenesis of idiopathic nephrotic syndrome, we iso-
lated a new gene, c-mip (for c-maf inducing protein) [7]. The nat-
ural isoform, c-mip, encodes for an 86 kDa protein. The predicted
structure of c-mip includes an N-terminal region containing a
pleckstrin homology domain (PH), a middle region characterized
by the presence of several interacting docking sites including, a
14-3-3 module, a PKC domain, an ERK domain, and an SH3 domain
similar to the p85 regulatory subunit of phosphatidylinositol 3-ki-
nase (PI3K) and a C-terminal region containing a leucin-rich repeat
(LRR) domain. The basal expression of c-mip transcript is very low
in adult tissues and the protein is not detectable in physiological
conditions. On the other hand, c-mip is upregulated at the mRNA
and protein levels in two major sites, the podocytes and the
peripheral lymphocytes during the active phase of the human dis-
ease (nephrotic syndrome). Our understanding about the role of c-
mip in cell signaling is far behind.
We report here that c-mip interacts with PI3 kinase complex
and displays a dual role in ERK signaling cascade. Although tran-
sient c-mip overexpression activates the MEK/ERK signaling, we
found that active ERK did not translocate in nucleus but it was
sequestrated in cytoplasmic compartment instead. Using two-hy-
brid system, we identiﬁed Dip1, a pro-apoptotic molecule, as a
partner of c-mip. We demonstrate also that overexpression of c-
mip induces an upregulation of death-associated protein kinase
DAP kinase, a known inhibitor of nuclear ERK translocation. These
results suggest that c-mip induces cytoplasmic retention of active
ERK, likely via a DAP kinase dependent mechanism.2. Materials and methods
2.1. Plasmid constructs
The c-mip expression plasmid construct was previously de-
scribed [8]. The Dip1 plasmid was kindly provided by Patricia J.
Gallagher (Indiana University School of Medicine, Indianapolis,
Indiana). The AP-1-luc, phRenilla-luc and pCRE-Luc vectors were
provided from Promega and Stratagene, respectively. The c-jun
cDNA was cloned in pcDNA3.1 expression vector (Invitrogen).
The Ghrelin receptor (GHSR) cDNA was cloned in a pcDNA3.1 vec-
tor and was used as a positive control for cAMP activation.
2.2. Cell culture, transient transfections and dual luciferase reporter
assay
The preparation of peripheral blood mononuclear cells (PBMCs),
cell culture conditions transients transfection experiments and
dual luciferase reporter assays were performed as previously de-
scribed [8].
2.3. RT-qPCR
The expression of cytokine mRNAs in the Jurkat cell line was as-
sessed by quantitative reverse transcription-polymerase chain
reaction (RT-qPCR), using the Light Cycler (Roche Diagnostics,
Somerville, NJ), as previously described [9]. GAPDH were used for
normalization of quantitative RT-PCR. The oligonucleotides used
to amplify interferon c, IL-4 and GAPDH transcripts have been pre-
viously described [10]. Jurkat cells were cultured at 0.3  106 cells/ml in complete RPMI medium and transfected with 1 lg DNA per
106 cells, using the Bio Rad gene pulser (Bio Rad, France), at
950 mF and 250 V. After electroporation, the cells were allowed
to recover for 4 h in conditioned medium, then cultured 18 h in
fresh medium containing Concanavalin A (Con A, 5 mg/ml) and
Phytohemagglutinin (PHA, 2 mg/ml). At the end of the incubation,
total RNA was isolated from cells and reverse transcribed as previ-
ously described [10].
2.4. Identiﬁcation of c-mip partners by yeast-two hybrid screening
The yeast-two hybrid technique has been previously described
[11]. Among proteins that we identiﬁed as interacting with c-
mip, we found the death-associated protein kinase (DAPK)-inter-
acting protein 1 (DIP1).
2.5. Co-immunoprecipitations and Western blots
All the primary antibodies used in this paper were purchased
from Cell signaling except for the antibodies against pI3K, p110
and p85a, subunits (Santa Cruz), the monoclonal anti-V5 (Invitro-
gen), the monoclonal anti-DAPK and anti-FLAG antibodies, and the
polyclonal ant-actin antibody (Sigma). The anti-c-mip polyclonal
antibody production has previously been described [8]. The afﬁnity
puriﬁed anti-rabbit and anti-mouse secondary antibodies were
purchased from Amersham and Santa Cruz, respectively.
Immunoprecipitation and Western blot experiments were
accomplished as previously described [8].
2.6. Statistical analysis
Statistical analysis of the data was performed using PRIZM 4 for
Macintosh (Graphpad Software, Inc., USA). Unpaired or Paired Stu-
dent t-tests were used. P value of less than 0.05 was considered
signiﬁcant.3. Results
3.1. Overexpression of c-mip induces the upregulation of the PI3 kinase
regulatory subunit, p85, but does not affect the expression of the
catalytic subunit, p110
Since the structure of c-mip contains a PH domain, we studied
the inﬂuence of c-mip on PI3 kinase, which plays a central role
in proximal signaling. Immunoblotting of PBMC protein lysates
showed that overexpression of c-mip induced an increased expres-
sion of p85a without affecting the expression of the catalytic sub-
unit p110 (Fig. 1A). Similar results were obtained in c-mip-
transfected Jurkat T cells (Fig. 1B). The expression level of p85a
in c-mip-overexpressing cells remains signiﬁcantly upregulated
upon activation with ConA/PHA (Fig. 1B), as compared with con-
trols (P < 0.05). The presence of a PH domain in c-mip led us to look
whether c-mip interacts with p85a. Protein lysates from c-mip and
empty vector-transfected cells were immunoprecipitated with
anti-p85a or anti-V5 and eluates were blotted with anti-V5 or
anti-p85a, respectively. Cross-immunoprecipitations showed that
c-mip interacts with endogenous p85a (Fig. 2, upper panel). We
then analyzed the interaction of p85a with p110 in empty vector
and c-mip-transfected cells. As shown in Fig. 2 (lower panel),
p110 was clearly immunoprecipitated with p85a in c-mip over-
expressing cells, while the level of p110 bound to p85a in empty
vector-transfected cells was below the detection limits. This result
suggests that c-mip increases the expression of p85a and interacts
with PI3 kinase complex. We next analyzed the expression of Lck,
an upstream signaling kinase. In resting T cells, Lck is maintained
Fig. 1. Overexpression of c-mip induces an upregulation of the subunit p85a of the
PI3 kinase. (A) Expression of p85a and p110 in PBMCs transiently transfected with
c-mip or empty vector (Ev). (B) Upper panel; Jurkat cells were transiently
transfected with c-mip expression plasmid or empty vector (Ev); and then were
or not stimulated for 1 h with Con A (5 lg/ml) and PHA (2 lg/ml); protein lysates
were sequentially immunoblotted with anti-c-mip (V5), anti-p85a and anti-p110
antibodies. Reprobing with anti-actin antibody shows that equal amounts of
proteins are loaded on the gel; lower panel, quantiﬁcations of p85a, using image J
software. The bands were normalized over actin and plotted as fold induction. The
data are expressed as the mean ± S.E.M and the two-tailed unpaired t-test is used
for statistical analysis (*P < 0.05 vs. Ev; 1P < 0.05 vs. Ev 1 h).
Fig. 2. C-mip interacts with the p85 subunit of PI3 kinase. Immunoprecipitation of
protein lysates from Jurkat cells co-transfected with c-mip or empty vector (Ev)
with anti-p85 or anti-V5. The eluates were blotted with anti-p110, anti-c-mip (V5)
or anti-p85 antibody, as indicated. The heavy immunoglobulin chain (IgH) band is
indicated.
Fig. 3. Overexpression of c-mip induces an inactivation of Lck. Jurkat cells were
transiently transfected with c-mip or empty vector (Ev) then, cells were or not
stimulated for 1 h with Con A (5 lg/ml) and PHA (2 lg/ml); protein lysates were
immunobloted with anti-phopho-lck recognizing the inactive form (Lck-tyr505);
then, the blots were sequentially reprobed with anti-total Lck and actin.
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nase that phosphorylates the major pool of Lck on tyrosine 505
(Lck-Y505) [12]. In unstimulated transfected cells, the expression
level of inactive Lck is similar in empty vector- and c-mip over-
expressing-cells. Upon activation by ConA/PHA, the level of Lck-
Y505 decreased signiﬁcantly in empty vector but no signiﬁcant
change was observed in c-mip transfected cells (Fig. 3), suggesting
that c-mip prevents the activation of Lck.
3.2. Overexpression of c-mip activates the MAPK-ERK1/2 pathway
Since c-mip exhibits three putative docking sites for ERK, we as-
sessed whether c-mip affects the MAPK signaling. In unstimulated
cells, the pMEK1/2 proteins were signiﬁcantly increased in c-mip
overexpressing cells, while they were below detection limits in
controls (Fig. 4A). Incubation with ConA/PHA increased the amount
of pMEK1/2 basically and in c-mip-transfected cells after 1-h post
stimulation, but the level declined at 6 h in empty vector-transfec-
ted cells, while it remained stable in c-mip overexpressing cells
(Fig. 4A). We next analyzed the expression of pERK1/2 that are
the immediate substrates of pMEK1/2. Overexpression of c-mipin Jurkat cells highly induced the expression of two 44 and
42 kDa-bands corresponding to phospho-ERK1 and phospho-
ERK2, respectively, while they were faintly detected in empty vec-
tor transfected cells (Fig. 4B). Further analysis of normal PBMC
transfected with c-mip showed also an upregulation of pERK2
but we did not observe signiﬁcant change of pERK1 (data not
shown).
We next determined the inﬂuence of c-mip on p38 MAPK. We
found that Jurkat cells transiently transfected with c-mip ex-
pressed a higher level of phosphorylated p38, as compared with
empty vector, while the total amount of protein did not change
(Fig. 4C). By contrast overexpression of c-mip does not affect the
phosphorylation status of the third MAPK pathway, JNK1/2
(Fig. 5A). This result led us to study the activation status of PKCh,
a regulator of JNK1/2. As shown in Fig. 5B, we did not detect signif-
icant change in phosphorylation level of PKCh. We obtained identi-
cal results in transient transfections of PBMC (data not shown).
Fig. 4. Overexpression of c-mip induces MEK1/2, ERK1/2 and p38 phosphorylation.
(A) Jurkat cells were transiently transfected with c-mip or its empty vector (Ev),
then stimulated for 1 h or not, with Con A (5 lg/ml) and PHA (2 lg/ml) and
immunoblotted with antibodies against c-mip (V5), phospho-MEK1/2 and actin. (B)
as (B) includes (C) Immunoblotting of protein lysates from Jurkat cells transiently
transfected with c-mip or empty vector (ev), with antibodies against c-mip (V5),
phospho-ERK1/2 and total ERK1/2, or phospho-p38 and total p38. Reprobing with
anti-actin antibody shows equal amount in each lane.
Fig. 5. Overexpression of c-mip does not induce PKCh and JNK activation. Jurkat
cells were transiently transfected with c-mip expression plasmid or empty vector,
then cells were or not stimulated 1 h with Con A (5 lg/ml) and PHA (2 lg/ml);
protein lysates were immunoblotted with antibodies against c-mip (V5), phospho-
JNK1/2 (A), or phospho-PKCh (B). Reprobing with anti-actin antibody shows equal
amount in each lane.
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Upon activation by MEK1/2, phosphorylated ERK1/2 (pERK1/2)
translocate to nucleus and activate their nuclear substrates such as
Elk1 and c-fos [13]. Both c-fos and c-jun bind to AP1 sites and acti-
vate the AP1 target genes. Inhibition of ERK signaling switches offthe AP1 signaling and blocks T cell activation [14]. The ﬁnding that
c-mip induced ERK1/2 phosphorylation led us to assess whether
AP-1 is activated following c-mip overexpression. Unexpectedly,
we found that c-mip overexpression did not induce AP-1 activation,
while it was highly induced by c-jun, which was used as positive
control (Fig. 6A). To test whether c-mip inﬂuences the expression
of cytokines, Jurkat cells were transfected with c-mip expression
plasmid or empty vector and 4 h later, cells were incubated over-
night with ConA/PHA. We then analyzed the expression of IFNg
and IL-4 by quantitative PCR. As shown in Fig. 6B, overexpression
of c-mip was associated with a downregulation of both cytokines.
Since AP1 activation requires the nuclear translocation of ERK1/
2, we sought to analyze the effect of c-mip on subcellular distribu-
tion of ERK1/2 by Western blotting of nuclear and cytosolic ex-
tracts. The lack of cytosolic protein contamination in the nuclear
extracts was controlled by immunoblotting with calpain, a protein
marker of the cytoplasm compartment (Fig. 7A). The expression of
c-mip protein was detectable mainly in cytoplasmic and, at least
degree, in nuclear fractions of c-mip overexpressing cells. The 42
and 44 kDa bands corresponding to pERK1/2 were only detected
in the cytosol, with a higher intensity in c-mip overexpressing
cells, as compared to empty vector overexpressing cells (Fig. 7A).
On the other hand, in untransfected Jurkat cells stimulated with
PMA, taken as control, pERK1/2 are detected in both, nuclear and
cytosolic fractions (Fig. 7B). We conclude that overexpression of
c-mip induces an upregulation of pERK1/2, which are conﬁned to
cytoplasmic compartment and thus precludes the AP1 activation.
3.4. C-mip interacts with DAP kinase-interacting protein-1 (Dip1)
The full-length c-mip cDNA was used as bait in a yeast-two-hy-
brid interaction screen [11]. One of positive clones encodes for
death associated protein kinase (DAPK)-interacting protein-1
(Dip-1), a 110 kDa protein that possesses an E3 ligase activity
and it has been shown to interact in vitro and in vivo with DAPK
[15]. We performed co-immunoprecipitation to conﬁrm whether
c-mip interacts with Dip1, using protein lysates from HEK cells
transfected with c-mip alone, c-mip and Dip1, or Dip1 alone. As
shown in Fig. 8A, Dip1 was clearly identiﬁed by immunoblotting
of c-mip immunoprecipitates from protein lysates transfected with
c-mip and Dip1 but not with c-mip alone. Conversely, we detected
c-mip in Dip1 immunoprecipitates from HEK cells cotransfected
with both expression plasmids but not with Dip1 alone. These re-
sults suggest that Dip 1 is a partner of c-mip.
3.5. Overexpression of c-mip induces an upregulation of DAP kinase
The ﬁnding that c-mip activates ERK and interacts with Dip1, a
regulator of DAPK, raised the possibility that the lack of ERK nucle-
ar translocation may result from abnormal expression of DAP ki-
nase. We tested the expression of DAPK in c-mip transfected
Jurkat cells. As shown in Fig. 8B, c-mip induced a signiﬁcant in-
crease of endogenous DAPK, which was barely detectable in empty
vector-transfected cells. The upregulation of DAPK by c-mip was
also observed in other cell types in vitro and in vivo (data not
shown), suggesting that the effect of c-mip on DAPK expression
is cell type-independent. We conclude that c-mip induces an
upregulation of DAPK, which might account for the retention of
ERK in cytoplasmic compartment.4. Discussion
C-mip is as new discovered gene of unknown function, which is
initially identiﬁed in T lymphocytes of patients with minimal
change nephrotic syndrome (MCNS) [7].
Fig. 6. C-mip mediated-Erk activation is inefﬁcient for AP1 activation. (A) Jurkat cells were transiently co-transfected with the c-mip or empty vector (Ev), and AP1-Luc
reporter plasmid; the phRL-null vector was used as an internal control for transfection and the c-jun expression plasmid was used as a positive control. Transfected cells were
cultured 24 h, then the luciferase activity was measured using the ‘‘Dual Luciferase reporter Assay”. The data are presented as relative luciferase activity (ﬁreﬂy luciferase/the
renilla luciferase). (B) Relative expression of IFNg and Il-4 transcripts from Jurkat cells transiently transfected with the c-mip expression plasmid or empty vector and then
treated with Con A and PHA as described in Section 2.
Fig. 7. Phospho-Erk does not translocate to nuclear compartment. (A) Protein lysates were immunoblotted with antibodies against c-mip (V5), phospho-ERK1/2 and calpain,
which was used to control the purity of the nuclear extract. Western blot of nuclear and cytosolic fractions shows the exclusive cytoplasmic retention of phospho-ERK1/2
following c-mip overexpression. This experiment is representative of four independent experiments. NE = nuclear extracts, CE = cytosolic extracts, NT = not treated. (B)
Control experiment showing the nuclear translocation of phospho-ERK1/2 in untransfected Jurkat cells treated with PMA for 30 min.
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acts with the PI3 kinase and increases the expression of p85 sub-
unit. (ii) c-mip inhibits the activation of Lck induced by ConA/
PHA; (iii) c-mip induces the phosphorylation of the MEK/ERK sig-
naling pathway but this activation is conﬁned to cytoplasmic com-
partment and (vi) c-mip interacts with Dip1 and upregulates DAPK.
The ﬁnding that c-mip maintains Lck in inactive conformation
suggests that c-mip acts as a repressor in downstream steps of sev-
eral signaling pathways. We demonstrate for the ﬁrst time that c-mip upregulates the subunit p85 of PI3K, without affecting the
p110 levels. Previous studies have shown that overexpression of
the wild-type p85 or the mutant p85 lacking the p110 binding site
inhibits the PI3K signaling by competing with the binding of the
p85–p110 dimer to insulin receptor substrate [16]. Conversely,
mice-deﬁcient in p85 display improved PI3K signaling [17]. In this
setting, the increase of p85a may interfere with the active refold-
ing of p110 and its subsequent binding to phosphoinositides. These
data suggest that free p85 competes with the p85/p110 dimer for
Fig. 8. C-mip interacts with Dip1 and upregulates death-associated protein kinase
(DAPK). (A) HEK cells were co-transfected with c-mip and Dip1 expression
plasmids, or empty vector. The upper panel shows inputs immunoblotted with
anti-FLAG (Dip1), anti-c-mip (left) and anti-actin antibodies (right). Middle panel,
protein lysates were immunoprecipitated with either anti-FLAG (left panel) or anti-
c-mip (right panel) and eluates were probed with antibodies indicated in the ﬁgure.
(B) Western-blot of DAPK in c-mip and empty vector-HEK transfected cells.
M. Kamal et al. / FEBS Letters 584 (2010) 500–506 505PIP2 binding and prevents activation of PI3K signaling. Recent
experimental evidences challenge this hypothesis [18]. Indeed, it
has been shown that monomeric p85, as p110, is unstable that
p85 bound top110 [19]. Our results showing an inability of Con/
PHA to activate Lck in the presence of c-mip may suggest that in-
creased expression of p85 is associated with an inhibition of PI3 ki-
nase signaling.
Inactivation of Lck in c-mip-overexpressing Jurkat cells induces
indirectly a constitutive activation of the ERK/p38 MAPK pathways,
such as reported in lck-deﬁcient cells [20]. This effect is not enough
to trigger AP1 activation given the inability of ERK to migrate in
nuclear compartment and to transactivate its target genes, like c-
fos and c-jun. We demonstrate that c-mip interacts with Dip1
and upregulates DAPK, another partner of Dip1. This ﬁnding may
explain how induction of c-mip leads to sequestrate ERK in the
cytoplasm compartment. In fact, it has been shown that DAPK
interacts with ERK and prevents its nuclear translocation, thus
inhibiting the ERK signaling in the nucleus [21]. This phenomenon
may represent a potential mechanism to prevent the developmentof an immune response since AP1 transcription factor is involved in
T cell response and cytokine production [22]. Accordingly, we ob-
served that overexpression of c-mip in activated Jurkat cells in-
duces a downregulation of IFNg and Il-4.
The results presented here for the ﬁrst time show that c-mip
interferes at different levels of cell signaling. The interaction with
PI3 kinase and the inactivation of Lck suggest that c-mip exerts a
negative regulatory role in proximal signaling. The fact that c-
mip interacts also with Dip1 suggest that c-mip is endowed with
proapoptoic properties. Future investigations are required to ex-
plore the role of c-mip in several signaling pathways as well as
its expression level in autoimmune diseases.
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